Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.31 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030445 | 0.88 | ALDH1A1 (0.33) | ERCC1FEN1ERCC4ALDH1A1CYP1A2 | |
| SCHEMBL4028095 | 0.86 | GABRP (0.32) | ERCC1FEN1ERCC4ALDH1A1CYP1A2 | |
| SCHEMBL4029058 | 0.85 | ERCC1 (0.36) | ERCC1FEN1ERCC4ALDH1A1CYP1A2 | |
| SCHEMBL4026719 | 0.83 | ALDH1A1 (0.34) | ERCC1FEN1ERCC4ALDH1A1MAPT | |
| SCHEMBL4029963 | 0.82 | ERCC1 (0.45) | ERCC1FEN1ERCC4ALDH1A1ADORA2A | |
| SCHEMBL1150702 | 0.78 | ADORA2A (0.42) | ALDH1A1ADORA2AADORA2BMAPT | |
| SCHEMBL4027808 | 0.78 | DHFR (0.31) | — | |
| SCHEMBL6631262 | 0.77 | SMN1; SMN2 (0.33) | ELANEERCC1FEN1ERCC4ALDH1A1 | |
| SCHEMBL4026532 | 0.76 | ERCC1 (0.33) | ERCC1FEN1ERCC4ALDH1A1CYP1A2 | |
| SCHEMBL4028309 | 0.74 | ALDH1A1 (0.34) | ERCC1FEN1ERCC4ALDH1A1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470113-B1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-01-07 | — | — | EP | disclosed |
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2005-06-16 | — | — | US | disclosed |
| EP-1470113-A1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003062211-A1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | POLR2A, POLR1E, POLR2E | ELANE 1183/4885PRTN3 72/4885ERCC1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.